Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Annual Goldman Sachs Global Healthcare Conference ...

Edgewise Therapeutics faces challenges with DMD/BMD programs, upcoming trial data concerns, and competitive risks.

Edgewise Therapeutics is primarily focused on developing novel treatments for conditions such as Hypertrophic Cardiomyopathy (HCM), Duchenne Muscular Dystrophy (DMD), and Becker Muscular Dystrophy ...

Detailed price information for Edgewise Therapeutics Inc (EWTX-Q) from The Globe and Mail including charting and trades.

May 8, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the first quarter of 2025 and ...

That professional was Guggenheim's Debjit Chattopadhyay, who initiated his Edgewise Therapeutics coverage with a buy recommendation, and price target of $41 per share. That's well more than double ...

Analyst Price Forecast Suggests 258.92% Upside As of April 2, 2025, the average one-year price target for Edgewise Therapeutics is $48.70/share. The forecasts range from a low of $30.30 to a high ...

Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) was downgraded by research analysts at Scotiabank from a “sector outperform” rating to a “sector perform” rating in a research ...

The last time I wrote about Edgewise Therapeutics, Inc. (NASDAQ:EWTX) it was in a Seeking Alpha article entitled "Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data." In the ...

Edgewise Therapeutics shares are trading lower by 23.3% during Wednesday's session. The company announced an approximate $200 million offering. Beat the market with ready-to-go trades and pro ...

April 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive top-line data of EDG-7500 from the Phase 2 ...

Edgewise Therapeutics stock opened at $28.01 on Friday. The stock has a market cap of $2.67 billion, a P/E ratio of -18.67 and a beta of 0.22. The company has a fifty day simple moving average of ...